As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório do Centro Universitário Braz Cubas |
Texto Completo: | https://repositorio.cruzeirodosul.edu.br/handle/123456789/346 |
Resumo: | Treatment with T-CAR or CAR-T cells (T-Lymphocytes with Chimeric Antigen Receptors) is one of the methods of cancer immunotherapy and has been used for the treatment of acute lymphoblastic leukemia (ALL) and other lymphomas. Having the T lymphocyte genetically modified with a CAR molecule on the surface that acts as a specific tumor cell receptor, which increases the destructive capacity of lymphocytes, since this modified molecule has the power to cause cytotoxicity to the antigen expressed on the surface of the infected cell. This literature review aimed to highlight the difficulties of this therapy, so that in the future modifications are made in order to improve it. It had a very large success with B-cell lymphoid neoplasms (recurrent and refractory), and there is also the possibility to treat some solid cancers. Acting specifically on the recognition of CD19, which is a marker of available B lineage on the tumor surface and which is expressed throughout the cell maturation process and found in most pathologies of lineage B, it suffers cytotoxicity causing reissue in the multiplication. This treatment is made from a process called leukopheresis. However the use of this treatment have some complexities and limitations, as any cancer treatment, CAR-T therapy also has side effects and other complexities that may be corrected in the future. The study of techniques aimed at reducing adverse effects can bring promising results. |
id |
CUB_babb075a70f46f05bb7761b0ae75944a |
---|---|
oai_identifier_str |
oai:repositorio.cruzeirodosul.edu.br:123456789/346 |
network_acronym_str |
CUB |
network_name_str |
Repositório do Centro Universitário Braz Cubas |
repository_id_str |
|
spelling |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica agudaThe CAR-T immunotherapy complexities for patients with acute lymphoblastic leukemiaImunoterapiaImunoterapiaCD19Receptor quimérico de antígenoCNPQ::OUTROS::BIOMEDICINATreatment with T-CAR or CAR-T cells (T-Lymphocytes with Chimeric Antigen Receptors) is one of the methods of cancer immunotherapy and has been used for the treatment of acute lymphoblastic leukemia (ALL) and other lymphomas. Having the T lymphocyte genetically modified with a CAR molecule on the surface that acts as a specific tumor cell receptor, which increases the destructive capacity of lymphocytes, since this modified molecule has the power to cause cytotoxicity to the antigen expressed on the surface of the infected cell. This literature review aimed to highlight the difficulties of this therapy, so that in the future modifications are made in order to improve it. It had a very large success with B-cell lymphoid neoplasms (recurrent and refractory), and there is also the possibility to treat some solid cancers. Acting specifically on the recognition of CD19, which is a marker of available B lineage on the tumor surface and which is expressed throughout the cell maturation process and found in most pathologies of lineage B, it suffers cytotoxicity causing reissue in the multiplication. This treatment is made from a process called leukopheresis. However the use of this treatment have some complexities and limitations, as any cancer treatment, CAR-T therapy also has side effects and other complexities that may be corrected in the future. The study of techniques aimed at reducing adverse effects can bring promising results.O tratamento com células T-CAR ou CAR-T (Linfócitos T com Receptores Antígenos Quiméricos) é um dos métodos da imunoterapia do câncer, e vem sendo usado para o tratamento da Leucemia Linfoblástica Aguda (LLA) e outros linfomas. Tendo o linfócito T modificado geneticamente, com uma molécula CAR de superfície, que atua como um receptor específico da célula tumoral e que aumenta a capacidade destrutiva dos linfócitos, já que esta molécula modificada tem o poder de causar citotoxicidade ao antígeno expresso na superfície da célula infectada. Esta revisão bibliográfica teve como objetivo salientar as dificuldades dessa terapia, para que no futuro sejam feitas modificações a fim de aprimorá-la. Essa terapia teve um sucesso muito grande com neoplasias linfoides de células B (recidiva e refratária), e há a possibilidade para tratar alguns cânceres sólidos. Agindo no reconhecimento do CD19, que é um marcador de linhagem B disponível na superfície tumoral e que é expresso durante todo o processo de maturação celular e encontrado na maioria das patologias de linhagem B, sofre citotoxidade causando reemissão em sua multiplicação. O tratamento é feito a partir do sangue coletado do paciente, e dessa amostra são retiradas as células T, num processo chamado leucoferese. Todavia, o tratamento tem algumas complexidades e limitações, pois assim como todo tratamento para o câncer, a terapia também possui efeitos adversos, além de outras complexidades que poderão ser corrigidas futuramente. Oss estudo de técnicas que visam diminuir os efeitos adversos podem trazer resultados promissores.Universidade Cidade de São PauloBrasilUNICID2020-02-18T18:57:11Z2020-02-18T18:57:11Z2019-12-05info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfGATTI, Bárbara Guimarães et al. As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda. Orientadora: Flavia Enira Gomes Pereira. 2019. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Cidade de São Paulo. 2019.https://repositorio.cruzeirodosul.edu.br/handle/123456789/346porTrabalho de Conclusão de CursoGatti, Barbara GuimarãesSabino, Bruna AmorimPinheiro, Bruna MunizTavares Filho, Claudiney MarquesSantos, Débora VicenteOliveira, Larissa Aparecida deChaves, Leandro Santos Ferreirainfo:eu-repo/semantics/openAccessreponame:Repositório do Centro Universitário Braz Cubasinstname:Centro Universitário Braz Cubas (CUB)instacron:CUB2020-03-30T15:10:24Zoai:repositorio.cruzeirodosul.edu.br:123456789/346Repositório InstitucionalPUBhttps://repositorio.brazcubas.edu.br/oai/requestbibli@brazcubas.edu.bropendoar:2020-03-30T15:10:24Repositório do Centro Universitário Braz Cubas - Centro Universitário Braz Cubas (CUB)false |
dc.title.none.fl_str_mv |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda The CAR-T immunotherapy complexities for patients with acute lymphoblastic leukemia |
title |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda |
spellingShingle |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda Gatti, Barbara Guimarães Imunoterapia Imunoterapia CD19 Receptor quimérico de antígeno CNPQ::OUTROS::BIOMEDICINA |
title_short |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda |
title_full |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda |
title_fullStr |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda |
title_full_unstemmed |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda |
title_sort |
As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda |
author |
Gatti, Barbara Guimarães |
author_facet |
Gatti, Barbara Guimarães Sabino, Bruna Amorim Pinheiro, Bruna Muniz Tavares Filho, Claudiney Marques Santos, Débora Vicente Oliveira, Larissa Aparecida de Chaves, Leandro Santos Ferreira |
author_role |
author |
author2 |
Sabino, Bruna Amorim Pinheiro, Bruna Muniz Tavares Filho, Claudiney Marques Santos, Débora Vicente Oliveira, Larissa Aparecida de Chaves, Leandro Santos Ferreira |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Gatti, Barbara Guimarães Sabino, Bruna Amorim Pinheiro, Bruna Muniz Tavares Filho, Claudiney Marques Santos, Débora Vicente Oliveira, Larissa Aparecida de Chaves, Leandro Santos Ferreira |
dc.subject.por.fl_str_mv |
Imunoterapia Imunoterapia CD19 Receptor quimérico de antígeno CNPQ::OUTROS::BIOMEDICINA |
topic |
Imunoterapia Imunoterapia CD19 Receptor quimérico de antígeno CNPQ::OUTROS::BIOMEDICINA |
description |
Treatment with T-CAR or CAR-T cells (T-Lymphocytes with Chimeric Antigen Receptors) is one of the methods of cancer immunotherapy and has been used for the treatment of acute lymphoblastic leukemia (ALL) and other lymphomas. Having the T lymphocyte genetically modified with a CAR molecule on the surface that acts as a specific tumor cell receptor, which increases the destructive capacity of lymphocytes, since this modified molecule has the power to cause cytotoxicity to the antigen expressed on the surface of the infected cell. This literature review aimed to highlight the difficulties of this therapy, so that in the future modifications are made in order to improve it. It had a very large success with B-cell lymphoid neoplasms (recurrent and refractory), and there is also the possibility to treat some solid cancers. Acting specifically on the recognition of CD19, which is a marker of available B lineage on the tumor surface and which is expressed throughout the cell maturation process and found in most pathologies of lineage B, it suffers cytotoxicity causing reissue in the multiplication. This treatment is made from a process called leukopheresis. However the use of this treatment have some complexities and limitations, as any cancer treatment, CAR-T therapy also has side effects and other complexities that may be corrected in the future. The study of techniques aimed at reducing adverse effects can bring promising results. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-12-05 2020-02-18T18:57:11Z 2020-02-18T18:57:11Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
GATTI, Bárbara Guimarães et al. As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda. Orientadora: Flavia Enira Gomes Pereira. 2019. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Cidade de São Paulo. 2019. https://repositorio.cruzeirodosul.edu.br/handle/123456789/346 |
identifier_str_mv |
GATTI, Bárbara Guimarães et al. As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda. Orientadora: Flavia Enira Gomes Pereira. 2019. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Cidade de São Paulo. 2019. |
url |
https://repositorio.cruzeirodosul.edu.br/handle/123456789/346 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Trabalho de Conclusão de Curso |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Cidade de São Paulo Brasil UNICID |
publisher.none.fl_str_mv |
Universidade Cidade de São Paulo Brasil UNICID |
dc.source.none.fl_str_mv |
reponame:Repositório do Centro Universitário Braz Cubas instname:Centro Universitário Braz Cubas (CUB) instacron:CUB |
instname_str |
Centro Universitário Braz Cubas (CUB) |
instacron_str |
CUB |
institution |
CUB |
reponame_str |
Repositório do Centro Universitário Braz Cubas |
collection |
Repositório do Centro Universitário Braz Cubas |
repository.name.fl_str_mv |
Repositório do Centro Universitário Braz Cubas - Centro Universitário Braz Cubas (CUB) |
repository.mail.fl_str_mv |
bibli@brazcubas.edu.br |
_version_ |
1798311351261593600 |